Lyell Immunopharma (LYEL) Operating Income (2020 - 2025)
Historic Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$37.3 million.
- Lyell Immunopharma's Operating Income rose 2623.9% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$342.9 million, marking a year-over-year decrease of 5793.72%. This contributed to the annual value of -$358.8 million for FY2024, which is 4524.02% down from last year.
- Per Lyell Immunopharma's latest filing, its Operating Income stood at -$37.3 million for Q3 2025, which was up 2623.9% from -$47.1 million recorded in Q2 2025.
- Lyell Immunopharma's Operating Income's 5-year high stood at -$14.8 million during Q4 2022, with a 5-year trough of -$201.1 million in Q4 2024.
- Moreover, its 5-year median value for Operating Income was -$55.6 million (2024), whereas its average is -$60.5 million.
- In the last 5 years, Lyell Immunopharma's Operating Income soared by 6890.07% in 2022 and then crashed by 30251.62% in 2023.
- Quarter analysis of 5 years shows Lyell Immunopharma's Operating Income stood at -$47.5 million in 2021, then soared by 68.9% to -$14.8 million in 2022, then plummeted by 302.52% to -$59.5 million in 2023, then tumbled by 238.02% to -$201.1 million in 2024, then surged by 81.48% to -$37.3 million in 2025.
- Its Operating Income was -$37.3 million in Q3 2025, compared to -$47.1 million in Q2 2025 and -$57.4 million in Q1 2025.